AUTL logo

AUTL
Autolus Therapeutics Ltd - ADR

3,626
Mkt Cap
$396.55M
Volume
1.52M
52W High
$2.70
52W Low
$1.15
PE Ratio
-1.38
AUTL Fundamentals
Price
$1.49
Prev Close
$1.47
Open
$1.50
50D MA
$1.48
Beta
1.38
Avg. Volume
1.82M
EPS (Annual)
-$1.08
P/B
2.97
Rev/Employee
$100,484.27
$578.99
Loading...
Loading...
News
all
press releases
Needham & Company LLC Reaffirms Buy Rating for Autolus Therapeutics (NASDAQ:AUTL)
Needham & Company LLC restated a "buy" rating and issued a $10.00 target price on shares of Autolus Therapeutics in a research report on Thursday...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Autolus Therapeutics Highlights obe-cel Momentum in ALL With New Real-World ROKA and Pediatric Data
Autolus Therapeutics (NASDAQ:AUTL) hosted an investor event focused on its acute lymphoblastic leukemia (ALL) program, featuring clinicians and investigators who discussed the treatment landscape...
MarketBeat·3d ago
News Placeholder
Apellis Pharmaceuticals (APLS) Moves 135.4% Higher: Will This Strength Last?
Apellis Pharmaceuticals (APLS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks·10d ago
News Placeholder
Autolus Therapeutics (NASDAQ:AUTL) Given New $10.00 Price Target at Mizuho
Mizuho lowered their price objective on Autolus Therapeutics from $12.00 to $10.00 and set an "outperform" rating for the company in a research report on Tuesday...
MarketBeat·11d ago
News Placeholder
Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Receives Consensus Rating of "Moderate Buy" from Analysts
Shares of Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Get Free Report) have been assigned an average rating of "Moderate Buy" from the seven brokerages that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has gi...
MarketBeat·14d ago
News Placeholder
Autolus Therapeutics' (AUTL) Buy Rating Reaffirmed at Needham & Company LLC
Needham & Company LLC reissued a "buy" rating and set a $10.00 price target on shares of Autolus Therapeutics in a research report on Friday...
MarketBeat·15d ago
News Placeholder
Autolus Therapeutics (NASDAQ:AUTL) Posts Earnings Results, Misses Estimates By $0.07 EPS
Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) posted its earnings results on Friday. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.27...
MarketBeat·15d ago
News Placeholder
Autolus Therapeutics Q4 Earnings Call Highlights
Autolus Therapeutics (NASDAQ:AUTL) executives highlighted a "very good first year of launch" for AUCATZYL during the company's fourth-quarter and full-year 2025 financial results call, pointing to $74.3 million in revenue recognized in 2025, expanded U.S. treatment-center activation, and early real...
MarketBeat·15d ago
News Placeholder
Autolus Therapeutics (NASDAQ:AUTL) Stock Rating Upgraded by Truist Financial
Truist Financial raised Autolus Therapeutics to a "strong-buy" rating in a research note on Wednesday...
MarketBeat·16d ago
News Placeholder
Mak Capital One LLC Buys 9,062,518 Shares of Autolus Therapeutics PLC Sponsored ADR $AUTL
Mak Capital One LLC lifted its stake in Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Free Report) by 53.5% in the third quarter, according to the company in its most recent disclosure with...
MarketBeat·25d ago
<
1
2
...
>

Latest AUTL News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.